Patrycja Głowacka
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Patrycja Głowacka has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Dorota Żakowska
Biological Threats Identification and Countermeasure Centre of the Military, Institute of Hygiene and Epidemiology, 24-100 Puławy, Poland
3 shared publications - Izabela Marczuk
Biological Threats Identification and Countermeasure Centre of the Military, Institute of Hygiene and Epidemiology, 24-100 Puławy, Poland
2 shared publications - Marta Ciesielska
Biological Threats Identification and Countermeasure Centre of the Military, Institute of Hygiene and Epidemiology, 24-100 Puławy, Poland
2 shared publications - Monika Ogórkiewicz
Biological Threats Identification and Countermeasure Centre of the Military, Institute of Hygiene and Epidemiology, 24-100 Puławy, Poland
2 shared publications - Patrycja Wójcicka
Chair and Department of Medical Microbiology, Medical University, 20-059 Lublin, Poland
2 shared publications - Paweł Rutyna
Chair and Department of Medical Microbiology, Medical University, 20-059 Lublin, Poland
2 shared publications
Latest Publications
- Open Access
- 16 December 2025
- Published by MDPI AG in Antibiotics
- Vol. 14 (12) , 1275
Analysis of the Concordance Between the Use of Phenotypic Screening Tests with the β-Lactamase Gene Profile in Selected Gram-Negative Bacteria
Background: There are many methods of identifying microbial resistance to therapeutic agents; however, they can generally be classified into two main categories: phenotypic and genotypic. The study aims to determine drug sensitivity and to analyze the correlation between the results obtained from cultures on commercial chromogenic media BrillianceTM CRE (OXOID) and BrillianceTM ESBL (OXOID) and the occurrence of specific resistance genes carbapenemase (IMP, NDM, VIM, KPC, OXA), ESBL β-lactamase (TEM, SHV, CTX-M), and AmpC (CMY, DHA), which will be used in drug sensitivity tests. Methods: The present study used bacteria, including Klebsiella pneumoniae, Acinetobacter baumannii, and Escherichia coli, obtained from patients hospitalized in military hospitals in Poland. All strains were plated on the commercial chromogenic media and subjected to antimicrobial susceptibility testing. Additionally, molecular assays detecting three main classes according to the mechanism of action, enzyme type carbapenemase (IMP, NDM, VIM, KPC, OXA), ESBL β-lactamase (TEM, SHV, CTX-M), and AmpC (CMY, DHA) were performed using the real-time PCR method. Results: The results of the studies indicate the presence of carbapenemases and ESBL genes. Among K. pneumoniae strains, the dominant gene was CTX-M-15 (88.89%), followed by the SHV (84.12%), NDM (46.03%), TEM (41.26%), KPC (34.92%), and OXA-48 (19.04%). In contrast, A. baumanii was dominated by carbapenemases from the OXA family (OXA-51 in 96.00% and OXA-24/40 in 84.00%). E. coli exhibits a high prevalence of CTX-M-15 (53.85%), TEM (46.15%), NDM (38.46%), and CMY-2 (30.77%). It was observed that the CTX-M-15 gene was commonly co-identified with SHV (n = 43). All tested strains grew on chromogenic BrillianceTM CRE medium. In the case of BrillianceTM ESBL medium, the genes determining the resistance mechanism were detected in 41.7% for A. baumannii, 53.8% for E. coli, and 100% for K. pneumoniae. Chromogenic media perfectly differentiate strains to species. A moderate positive correlation of the occurrence of the antibiotic resistance genes was observed for OXA-51 and OXA-24/40 genes, which were resistant to meropenem (rho = 0.45, p < 0.001). K-means cluster analysis performed on integrated genotype–phenotype data allowed for the identification of three distinct clusters characterized by distinct resistance gene profiles. These results demonstrate that selective agar media enable faster identification compared to other conventional techniques; however, the obtained results should be confirmed by other validated phenotypic methods, and, if possible, by a molecular assay.
- 16 December 2025
- Published by MDPI AG in Antibiotics
- Vol. 14 (12) , 1275
Open AccessAnalysis of the Concordance Between the Use of Phenotypic Screening Tests with the β-Lactamase Gene Profile in Selected Gram-Negative Bacteria
Background: There are many methods of identifying microbial resistance to therapeutic agents; however, they can generally be classified into two main categories: phenotypic and genotypic. The study aims to determine drug sensitivity and to analyze the correlation between the results obtained from cultures on commercial chromogenic media BrillianceTM CRE (OXOID) and BrillianceTM ESBL (OXOID) and the occurrence of specific resistance genes carbapenemase (IMP, NDM, VIM, KPC, OXA), ESBL β-lactamase (TEM, SHV, CTX-M), and AmpC (CMY, DHA), which will be used in drug sensitivity tests. Methods: The present study used bacteria, including Klebsiella pneumoniae, Acinetobacter baumannii, and Escherichia coli, obtained from patients hospitalized in military hospitals in Poland. All strains were plated on the commercial chromogenic media and subjected to antimicrobial susceptibility testing. Additionally, molecular assays detecting three main classes according to the mechanism of action, enzyme type carbapenemase (IMP, NDM, VIM, KPC, OXA), ESBL β-lactamase (TEM, SHV, CTX-M), and AmpC (CMY, DHA) were performed using the real-time PCR method. Results: The results of the studies indicate the presence of carbapenemases and ESBL genes. Among K. pneumoniae strains, the dominant gene was CTX-M-15 (88.89%), followed by the SHV (84.12%), NDM (46.03%), TEM (41.26%), KPC (34.92%), and OXA-48 (19.04%). In contrast, A. baumanii was dominated by carbapenemases from the OXA family (OXA-51 in 96.00% and OXA-24/40 in 84.00%). E. coli exhibits a high prevalence of CTX-M-15 (53.85%), TEM (46.15%), NDM (38.46%), and CMY-2 (30.77%). It was observed that the CTX-M-15 gene was commonly co-identified with SHV (n = 43). All tested strains grew on chromogenic BrillianceTM CRE medium. In the case of BrillianceTM ESBL medium, the genes determining the resistance mechanism were detected in 41.7% for A. baumannii, 53.8% for E. coli, and 100% for K. pneumoniae. Chromogenic media perfectly differentiate strains to species. A moderate positive correlation of the occurrence of the antibiotic resistance genes was observed for OXA-51 and OXA-24/40 genes, which were resistant to meropenem (rho = 0.45, p < 0.001). K-means cluster analysis performed on integrated genotype–phenotype data allowed for the identification of three distinct clusters characterized by distinct resistance gene profiles. These results demonstrate that selective agar media enable faster identification compared to other conventional techniques; however, the obtained results should be confirmed by other validated phenotypic methods, and, if possible, by a molecular assay.
- Open Access
- 30 October 2025
- Published by Institute of Rural Health in Annals of Agricultural and Environmental Medicine
Brucella and Ochrobactrum – differences and similarities
Introduction and objective: Brucella and Ochrobactrum are genetically-related strains of bacteria belonging to the same Alphaproteobacteria class, due to their evolutionary origin. However, the two strains are distinct species. Brucella is the genus of bacteria that causes the infectious...
- 30 October 2025
- Published by Institute of Rural Health in Annals of Agricultural and Environmental Medicine
Open AccessBrucella and Ochrobactrum – differences and similarities
Introduction and objective: Brucella and Ochrobactrum are genetically-related strains of bacteria belonging to the same Alphaproteobacteria class, due to their evolutionary origin. However, the two strains are distinct species. Brucella is the genus of bacteria that causes the infectious...
- Open Access
- 19 September 2019
- Published by Institute of Rural Health in Annals of Agricultural and Environmental Medicine
- Vol. 26 (3) , 392-395
Protective antigen domain 4 of Bacillus anthracis as a candidate for use as vaccine for anthrax
Existing research for using the protective antigen (PA) of Bacillus anthracis as a vaccine component shows that protection against anthrax may be obtained using fragments of this protein. The aim of the research is to check whether the selected protein fragment of the protective antigen (domain 4) encoded by an appropriate nucleotide sequence of gene pag of B. anthracis, was expressed in the bacterial system of E. coli. In order to examine the selected sequence of the pag gene, a PCR reaction and a highly effective TOPO cloning strategy were used, followed by purification of the recombinant proteins and their detection by a western-blot method. In the planning of the PA4 antigen expression a higher level of effectiveness in production of small protein - domain 4 - was anticipated. As a result, the 139 amino acids protein fragment of B. anthracis PA (domain 4) was isolated. The research may have found the basis for in vivo research aimed at finding potential anthrax vaccine components.
- 19 September 2019
- Published by Institute of Rural Health in Annals of Agricultural and Environmental Medicine
- Vol. 26 (3) , 392-395
Open AccessProtective antigen domain 4 of Bacillus anthracis as a candidate for use as vaccine for anthrax
Existing research for using the protective antigen (PA) of Bacillus anthracis as a vaccine component shows that protection against anthrax may be obtained using fragments of this protein. The aim of the research is to check whether the selected protein fragment of the protective antigen (domain 4) encoded by an appropriate nucleotide sequence of gene pag of B. anthracis, was expressed in the bacterial system of E. coli. In order to examine the selected sequence of the pag gene, a PCR reaction and a highly effective TOPO cloning strategy were used, followed by purification of the recombinant proteins and their detection by a western-blot method. In the planning of the PA4 antigen expression a higher level of effectiveness in production of small protein - domain 4 - was anticipated. As a result, the 139 amino acids protein fragment of B. anthracis PA (domain 4) was isolated. The research may have found the basis for in vivo research aimed at finding potential anthrax vaccine components.